31.65

0.57% -0.18

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $31.65, with a volume of 465.35K. It is down -0.57% in the last 24 hours and down -7.51% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Previous Close:

$31.83

Open:

$32.21

24h Volume:

465.35K

Relative Volume:

0.46

Market Cap:

$3.59B

Revenue:

$14.09M

Net Income/Loss:

$-176.94M

P/E Ratio:

-14.72

EPS:

-2.15

Net Cash Flow:

$-141.24M

1W Performance:

-7.91%

1M Performance:

-7.51%

6M Performance:

+51.29%

1Y Performance:

+35.14%

1-Day Range:

$31.39

$32.21

1-Week Range:

$30.97

$34.87

52-Week Range:

$14.06

$42.00

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	31.65	3.61B	14.09M	-176.94M	-141.24M	-2.15
VRTX Vertex Pharmaceuticals Inc	441.36	111.36B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	733.04	77.98B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	800.01	50.33B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	359.27	47.46B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	338.19	37.43B	4.98B	69.59M	525.67M	0.5197

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Resumed	H.C. Wainwright	Buy
Aug-25-25	Initiated	Wells Fargo	Overweight
Jul-17-25	Initiated	Goldman	Neutral
Jun-17-25	Initiated	Citigroup	Buy
Jun-10-25	Initiated	Stifel	Buy
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

02:32 AM

Responsive Playbooks and the NAMSW Inflection - Stock Traders Daily

02:32 AM

Jan 17, 2026

Aug Intraday: Will NewAmsterdam Pharma Company NV benefit from seasonalityJuly 2025 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn

Jan 17, 2026

Jan 16, 2026

Fed Meeting: Is NewAmsterdam Pharma Company NV Equity Warrant exposed to political riskPortfolio Return Summary & Daily Oversold Bounce Ideas - baoquankhu1.vn

Jan 16, 2026

Gains Report: What is the implied volatility of Drugs Made In America Acquisition Corp Equity RightWeekly Trade Analysis & AI Enhanced Execution Alerts - baoquankhu1.vn

Jan 16, 2026

First Week of March 20th Options Trading For NewAmsterdam Pharma (NAMS) - Nasdaq

Jan 16, 2026

Jan 15, 2026

Relative Strength Alert For NewAmsterdam Pharma Company - Nasdaq

Jan 15, 2026

Aug Action: Does NewAmsterdam Pharma Company NV Equity Warrant align with a passive investing strategy2025 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn

Jan 15, 2026

Jan 14, 2026

Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Volatility - Yahoo Finance

Jan 14, 2026

Jan 13, 2026

Aug Rallies: How NewAmsterdam Pharma Company NV stock compares to market leadersPortfolio Update Summary & High Return Trade Guides - Bộ Nội Vụ

Jan 13, 2026

NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech With 46% Upside Potential - DirectorsTalk Interviews

Jan 13, 2026

Jan 12, 2026

NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 - Investing.com

Jan 09, 2026

NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 By Investing.com - Investing.com South Africa

Jan 09, 2026

NewAmsterdam Pharma Updates on Obicetrapib Clinical Development and EMA Approval Timeline - Quiver Quantitative

Jan 09, 2026

Drug in late-stage tests cuts cholesterol and an Alzheimer’s marker - Stock Titan

Jan 09, 2026

Can NewAmsterdam Pharma Company N.V. stock continue upward trendModel Comparison & how to pick the right width - Улправда

Jan 09, 2026

Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts high net worth investorsJuly 2025 Selloffs & Reliable Volume Spike Alerts - ulpravda.ru

Jan 09, 2026

Jan 08, 2026

Can NewAmsterdam Pharma Company N.V. (KH6) stock hold up in economic slowdownMarket Activity Summary & AI Forecasted Entry and Exit Points - Улправда

Jan 08, 2026

Is NewAmsterdam Pharma Company N.V. Equity Warrant stock near bottom after declineAnalyst Upgrade & Verified Chart Pattern Signals - ulpravda.ru

Jan 08, 2026

Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from strong economy2025 Historical Comparison & Community Consensus Stock Picks - Улправда

Jan 08, 2026

What dividend safety score for NewAmsterdam Pharma Company N.V. stock2025 Technical Patterns & Low Risk High Reward Ideas - Улправда

Jan 08, 2026

Jan 07, 2026

Louise Frederika Kooij Sells 2,647 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat

Jan 07, 2026

Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 6,000 Shares of Stock - MarketBeat

Jan 07, 2026

Is NewAmsterdam Pharma Company N.V. stock positioned for long term growthEconomic Indicators Overview & Affordable Growth Investments - Улправда

Jan 07, 2026

A Look At NewAmsterdam Pharma (NAMS) Valuation As Late Stage CETP Trial Progress Draws Investor Attention - Sahm

Jan 07, 2026

Jan 06, 2026

NewAmsterdam Pharma (NAMS) Stock Analysis: Unveiling a 43.88% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Jan 06, 2026